LX214 Ophthalmic Solution
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for LX214 Ophthalmic Solution, covering 2012-06-22 to 2012-06-22. Get the full timeline:
Most recent: Clinical Trial Update: A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS) [Phase 1]